Mineralys Therapeutics, Inc.
NASDAQ:MLYSBiotechnology
+$0.37 today
- Market cap
- $1.22B
- Beta
- 0.56
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$1.83
Volume 1.39M
Average 1.48M
MLYS Total Liabilities
Everything the company owes to creditors and other parties.
Mineralys Therapeutics, Inc.NASDAQ: MLYS
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities rises 427.4% from a year ago
Total liabilities stood at $116.94M at the end of Q2 FY2026, up 427.4% from a year earlier and up 694.5% from the prior quarter. Over 3 fiscal years it compounded at -55.1% a year.
Context
- Total liabilities amounted to 17.5% of total assets at the end of Q2 FY2026, up 10.9 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +427.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 15.11M USD
- Year-over-year change
- +3.2%
- 4-year CAGR
- -18.4%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.11M | +3.2% |
| FY2024 | 2024-12-31 | 14.65M | +39.7% |
| FY2023 | 2023-12-31 | 10.48M | -93.7% |
| FY2022 | 2022-12-31 | 166.71M | +389.6% |
| FY2021 | 2021-12-31 | 34.05M | — |
Total Liabilities vs competitors
How MLYS compares with its peers on the latest reported figures
- MLYS's Jun 2026 total liabilities of $116.94M is the 3rd highest of the 7 companies compared; the peer median is $63.85M.
- Its year-over-year change of +427.4% is the highest of 7, against a peer median of +40.0%.
- Total liabilities amounts to 17.5% of total assets for MLYS, versus a peer median of 32.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $825.65M | +77.6% | -8.0% | 97.3% | |
| Jun 2026 | $125.23M | +13.6% | +33.7% | 23.5% | |
| Jun 2026 | $116.94M | +427.4% | -55.1% | 17.5% | |
| Mar 2026 | $78.01M | +91.3% | -4.6% | 18.6% | |
| Mar 2026 | $49.69M | +17.8% | +6.2% | 49.4% | |
| Mar 2026 | $26.7M | +60.1% | +79.3% | 41.5% | |
| Mar 2026 | $5.85M | +19.9% | +27.0% | 11.0% | |
| Peer median (excluding MLYS) | $63.85M | +40.0% | +16.6% | 32.5% | |
Competitors are the stored peer set for MLYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 10.61M | 87.7M | 49.3M | 114.09M | 172.92M |
| Short-term Investments | 0 | 22.41M | 187.26M | 84.1M | 483.71M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 50K | 2.7M | 12.54M | 7.16M | 4.75M |
| Total Current Assets | 11.12M | 112.81M | 249.1M | 205.35M | 661.39M |
| Property, Plant & Equipment (Net) | 0 | 0 | 0 | 53K | 38K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 2.48M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3K | 1.63M | 51K | 499K | 382K |
| Total Non-current Assets | 3K | 1.63M | 2.53M | 552K | 420K |
| Total Assets | 11.13M | 114.44M | 251.64M | 205.9M | 661.81M |
| Account Payables | 763K | 1.91M | 601K | 479K | 2.02M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 313K | 665K | 1.6M | 3.58M | 7.56M |
| Total Current Liabilities | 5.05M | 8.07M | 10.48M | 14.65M | 15.11M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 29M | 158.64M | 0 | 0 | 0 |
| Total Non-current Liabilities | 29M | 158.64M | 0 | 0 | 0 |
| Total Liabilities | 34.05M | 166.71M | 10.48M | 14.65M | 15.11M |
| Common Stock | 1K | 1K | 4K | 5K | 8K |
| Retained Earnings | (23.01M) | (52.81M) | (124.71M) | (302.52M) | (457.17M) |
| Accumulated OCI | 0 | 0 | (251.64M) | 0 | 0 |
| Other Stockholders Equity | (29M) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (22.93M) | (52.27M) | 241.15M | 191.26M | 646.69M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | (10.61M) | (87.7M) | (49.3M) | (114.09M) | (172.92M) |
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
Intrinsic Alpha fair value
Locked
Current Price
$13.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.